Caricamento...
Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
Urothelial carcinoma is one of the most common cancers in the United States, yet outcomes are historically suboptimal. Since 2016, the approval of five programmed cell death 1 and programmed death-ligand 1 immune checkpoint inhibitors for locally advanced and metastatic urothelial carcinoma has led...
Salvato in:
| Pubblicato in: | J Cancer Immunol (Wilmington) |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8276975/ https://ncbi.nlm.nih.gov/pubmed/34263255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.33696/cancerimmunol.3.047 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|